The DOI matches its Crossref record; 153 of the 153 references it cites were found in a registry or an index.
Translating Glutamate: From Pathophysiology to Treatment
Open accessAbstract
On 21 to 22 June 2010, the Institute of Medicine Forum on Neuroscience and Nervous System Disorders, Board on Health Sciences Policy, discussed the role of glutamate in neuropsychiatric disease at the meeting “Glutamate-Related Biomarkers in Drug Development for Disorders of the Nervous System.”
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“As in humans, treatment of adult rodents with NMDAR antagonists triggers acute schizophrenia-related behaviours, including deficits in attention and/ or vigilance, learning and memory and sensory gating, broadly mimicking the symptoms of patients with schizophrenia 10,15,23,24 .”
From Linking early-life NMDAR hypofunction and oxidative stress in schizophrenia pathogenesis (2016) · cites this paper as [15]
In the citing paper
“Subsequent behavioral, neurophysiological and functional imaging studies have supported the NMDAR hypofunction hypothesis of schizophrenia, showing that indicators of sensory dysfunction in patients with schizophrenia -such as mismatch negativity (MMN) and changes in auditory and visual event-related potentials -can be mimicked by treating otherwise healthy individuals with NMDAR antagonists 12,15”
From Linking early-life NMDAR hypofunction and oxidative stress in schizophrenia pathogenesis (2016) · cites this paper as [15]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Common polygenic variation contributes to risk of schizophrenia and bipolar disorder
The International Schizophrenia Consortium (2009) · Nature · doi:10.1038/nature08185 · Cited by 4,821
Trivedi, M. H., Rush, A. J., Wisniewski, S. R., Nierenberg, A. A., Warden, D., Ritz, L., Norquist, G., Howland, R. H., Lebowitz, B., McGrath, P. J., et al. (2006) · American Journal of Psychiatry · doi:10.1176/appi.ajp.163.1.28 · Cited by 3,879
Antidepressant effects of ketamine in depressed patients
Berman, R. M., Cappiello, A., Anand, A., Oren, D. A., Heninger, G. R., Charney, D. S., & Krystal, J. H. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00230-9 · Cited by 3,856
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Zarate, C. A., Singh, J. B., Carlson, P. J., Brutsche, N. E., Ameli, R., Luckenbaugh, D. A., Charney, D. S., & Manji, H. K. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.8.856 · Cited by 3,766
Self-citationKrystal, J. H. (1994) · Archives of General Psychiatry · doi:10.1001/archpsyc.1994.03950030035004 · Cited by 3,330
Recent advances in the phencyclidine model of schizophrenia
(1991) · American Journal of Psychiatry · doi:10.1176/ajp.148.10.1301 · Cited by 2,904
Self-citationmTOR-Dependent Synapse Formation Underlies the Rapid Antidepressant Effects of NMDA Antagonists
Li, N., Lee, B., Liu, R.-J., Banasr, M., Dwyer, J. M., Iwata, M., Li, X.-Y., Aghajanian, G., & Duman, R. S. (2010) · Science · doi:10.1126/science.1190287 · Cited by 2,881
The Neural Basis of Addiction: A Pathology of Motivation and Choice
Kalivas, P. W., & Volkow, N. D. (2005) · American Journal of Psychiatry · doi:10.1176/appi.ajp.162.8.1403 · Cited by 2,757
Self-citationGoldstein, R. Z., & Volkow, N. D. (2002) · American Journal of Psychiatry · doi:10.1176/appi.ajp.159.10.1642 · Cited by 2,667
Self-citationSchizophrenia genes, gene expression, and neuropathology: on the matter of their convergence
Harrison, P. J., & Weinberger, D. R. (2005) · Molecular Psychiatry · doi:10.1038/sj.mp.4001558 · Cited by 2,020
Research works printed but not linked: 2
- Borroni E., Wong D. F., Wallace T. L., Zhou Y., Kumar A., Pinard E., Alberati D., Partial occupancy of the glycine transporter type 1 in monkey by RG1678 leads to efficacy in a model of prefrontal cortical function. Schiz. Bull. 37 (Suppl. 1), 296–297 (2011).
- Umbricht D., Yoo K., Youssef E., Dorflinger E., Martin-Facklam M., Bausch A., Arrowsmith R., Alberati D., Marder S. R., Santarelli L., Glycine transporter type 1 (GLYT1) inhibitor RG1678: Positive results of the proof-of-concept study for the treatment of negative symptoms in schizophrenia. Neuropsychopharmacology 35, S320–S321 (2010).
Cited by
Sorted by citations
Electrical synapses and their functional interactions with chemical synapses
Pereda, A. E. (2014) · Nature reviews. Neuroscience · doi:10.1038/nrn3708 · Cited by 855
Ayalew, M., Le-Niculescu, H., Levey, D. F., Jain, N., Changala, B., Patel, S. D., Winiger, E. A., Breier, A. F., Shekhar, A., AMDUR, R. L., et al. (2012) · Molecular Psychiatry · doi:10.1038/mp.2012.37 · Cited by 390
Auditory dysfunction in schizophrenia: integrating clinical and basic features
Javitt, D. C., & Sweet, R. A. (2015) · Nature reviews. Neuroscience · doi:10.1038/nrn4002 · Cited by 377
Self-citationJavitt, D. C., Zukin, S. R., Heresco-Levy, U., & Umbricht, D. (2012) · Schizophrenia Bulletin · doi:10.1093/schbul/sbs069 · Cited by 322
Self-citationLinking early-life NMDAR hypofunction and oxidative stress in schizophrenia pathogenesis
Hardingham, G. E., & Do, K. Q. (2016) · Nature Reviews Neuroscience · doi:10.1038/nrn.2015.19 · Cited by 304
Metadata
- Authors
- Javitt, D. C., Schoepp, D., Kalivas, P. W., Volkow, N. D., Zarate, C., Merchant, K., Bear, M. F., Umbricht, D., Hajos, M., Potter, W. Z., & Lee, C.-M.
- Affiliations
- Columbia University (US)
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
- Medical University of South Carolina (US)
- National Institute on Drug Abuse (US)
- National Institutes of Health (US)
- Eli Lilly (United States) (US)
- Massachusetts Institute of Technology (US)
- F. Hoffmann-La Roche AG (CH)
- Neuroscience Department, CNS Discovery, Pfizer Global Research and Development, Groton, CT 06340, USA.
- Foundation for the National Institutes of Health (US)
- AstraZeneca (Sweden) (SE)
- Corresponding author
- Javitt, Daniel C.
- ORCID
- Venue
- Science Translational Medicine
- Published
- 2011-09-28
- Volume
- 3
- Issue
- 102
- Pages
- 102mr2-102mr2
- ISSN
- 1946-6234 (ISSN-L)
- 1946-6242
- PMC
- PMC3273336
- OpenAlex
- W1559706924
- Cited by
- 168
- References
- 150
- Citations by year
- 2026: 1 · 2025: 5 · 2024: 7 · 2023: 8 · 2022: 5 · 2021: 12 · 2020: 11 · 2019: 14 · 2018: 10 · 2017: 10 · 2016: 5 · 2015: 19 · 2014: 19 · 2013: 19 · 2012: 22
- Type
- conference abstract
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Science Translational Medicine (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- DSpace@MIT (Massachusetts Institute of Technology) (submittedVersion, cc-by-nc-sa)
- Funders
- National Institutes of Health
- National Institute of Mental Health (R37MH049334, R37MH49334, P50MH086385, ZIAMH002857)
- National Institute on Drug Abuse (R01DA03383, R01DA003383)
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (R01HD046943)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Amino Acid Enzymes and Metabolism
- Keywords
- glutamate, glutamatergic neurotransmission, neuropsychiatric disorders, schizophrenia, drug addiction, autism spectrum disorder, depression, biomarkers, translational model, drug development, target engagement
- MeSH terms
- Animals, Clinical Trials as Topic, Congresses as Topic, Humans, Nervous System Diseases, Neurotransmitter Agents, Glutamic Acid, Mice, Translational Research, Biomedical
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
